Orion Office REIT Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Orion Office REIT Inc trades at $2.11 (market cap $119.79M), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 43.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.81% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 34 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| ONL | ORKA | |
|---|---|---|
Market Cap | $119.79M | $5.18B |
Volume | 378,596 | 490,798 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $113.08 |
52-Week Low | $1.93 | $26.19 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $536.73M | $4.31B |
Dividend Yield | 3.81% | — |
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.10, down 2.33% today, with a bearish technical signal from moving averages. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear mixed with low P/S (0.84) and P/B (0.19) ratios but negative profitability margins. Analyst consensus is evenly split between Buy and Hold ratings.
The outlook remains challenging due to ongoing revenue declines and negative margins, though the deep discount to book value and recent earnings beat offer potential upside. Key risks include high debt levels, weak office property demand, and sustained cash flow pressures. Investors should weigh the value proposition against fundamental weaknesses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →